Investor Presentation
November 2020
1
Developing a New Class of Immunotherapies and Vaccines
We are committed to making immunotherapy and vaccines more effective, more broadly applicable, and more widely available to patients.
TICKER
IMV (Nasdaq & TSX)
MARKET CAP (Nov.11)
- $US 270 M /
- $CAD 353 M
Cash and cash equiv. (Sept. 30): 54.7 M CDN$ / 40.9 M US $
OUTSTANDING SHARES (Nov.11)
Basic : 67.1M
Fully diluted : 71.6M
© 2020 IMV Inc. All rights reserved.
2
Investment Highlights
DPX™ delivery platform to create a novel class of vaccines and immunotherapies
Unique mechanism of action that generates targeted and sustained stimulation of immune system
Immune cell activation that can be maintained over an extended period with limited side effects
Clinically-demonstrated activity in solid / hematologic cancers as well as infectious diseases
DPX-Survivac, lead oncology program focused on unmet medical needs
Demonstrated tumor regression in solid and hematologic cancers
Excellent safety profile across all clinical Phase 1 and 2 studies (N=350)
DPX-COVID-19, our answer to the global pandemic
Designed to generate prolonged antiviral protection
Potential ability to serve an older / immunocompromised population
Fully synthetic formulation that allows rapid, cost-efficientscale-up manufacturing
Milestones
Additional phase 2 DPX Survivac combination clinical data in DLBCL at ASH (Dec. 6, 2020)
Update on DPX-Survivac/CPA in late-stage ovarian cancer (Dec. 3, 2020) and for the basket trial (Q1 2021)
Initiate DPX COVID-19 Phase 1/2 trial before year end 2020
© 2020 IMV Inc. All rights reserved. | 3 |
Leadership Team with Strong Track Record in Drug Development
Frederic Ors, MSc, MBA | Marie-Eve Charrois, MA | Brittany Davison, CPA, CA | |||
Chief Executive Officer | Vice President, Regulatory | Vice President, Finance | |||
Affairs | |||||
Pierre Labbé, CPA | Stephan Fiset, MSc, MBA | Ryan Marshall, MSc | |||
Chief Financial Officer | Vice-President, Clinical | Vice President, Project | |||
Research | Management and Operations | ||||
Andrew Hall | Tariq Massad, PhD, PMP | Marianne Stanford, PhD | |||
Chief Business Officer | Vice President, Process Dev | Vice-President, Research & | |||
and Manufacturing | Development | ||||
Joanne Schindler, DVM, MD | Annie Tanguay, BSc | ||
Chief Medical Officer | Senior Vice President, | ||
Quality and Regulatory | |||
© 2020 IMV Inc. All rights reserved. | 4 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
IMV Inc. published this content on 16 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2020 14:42:08 UTC